It takes more time to build sales when you are actually having to establish the market in the first place (which was the case with Lovaza). With the launch of Vascepa, we should be seeing better market share numbers in the launch phase, but so far, it has not been that great of a start.
Reliant had an 800 person sales force when they launched Omacor (Lovaza)
It was also easier then to drive share with a new product (not as much generic competition, not as much push back from managed care)
More patients were actually insured back then- 3 million people lost their benefits at the end of last year
It was a completely different ballgame back then
Obamacare is setting in, and the door is slamming shut for products to gain entry into the lipid lowering market
Not our fault by any means. 8, even 5 years ago we would be rocking
DENIAL!
1. It was not easier because there wasn't an omega 3 prescription market established.
2. I'll give you rep numbers, however, Reliant had to directly compete against Antara with the same sales force.
3. Managed Care sucked at first with Omacor, practically no Med D coverage...sound familiar?
4. There are plenty of millions of insured patients right now.
5. Vascepa is already IN the market, so Obama has nothing to do with it.
I get it, you are making excuses because you were fed a pipe dream. Fact is you have an inferior triglyceride lowering drug, and you are going up against a better sales force with more resources.
GSK puke, please go kiss the doctor's ass so you get a good rating and leave the selling to us who get paid to move product. Quit living in the Wonder Years Kevin, this is 2013 and Amarin is out performing big pharma in their launches that came in with a 2 year pre-launch and brand recognition. NO excuses, we are taking this product to the top, in due time . We are taking your market share and as experience and results grows, the growth will be exponential. p.s. Kiss my arse.
GSK puke, please go kiss the doctor's ass so you get a good rating and leave the selling to us who get paid to move product. Quit living in the Wonder Years Kevin, this is 2013 and Amarin is out performing big pharma in their launches that came in with a 2 year pre-launch and brand recognition. NO excuses, we are taking this product to the top, in due time . We are taking your market share and as experience and results grows, the growth will be exponential. p.s. Kiss my arse.
No! home knows it's over, been over. We have lost 27 reps 4 managers 1 area director and training... and marketing or lack there of, you got a million dollar $$$ slash and two morons in charge.. no offense, It's over get out, we are going down with Mr. Zee ship. He has his money you won't
Vascepa is clearly a superior product. Period end of story. The rest is not Important.we developed a better product, it will eventually be the standard.
Vascepa is clearly a superior product. Period end of story. The rest is not Important.we developed a better product, it will eventually be the standard.
Sales are increasing week over week and more insurances are now covering at Tier 2. Some of the insurances are already covering Trigs > 200 including Tricare. Slow and steady will get us there.
Vascepa is clearly a superior product. Period end of story. The rest is not Important.we developed a better product, it will eventually be the standard.
Sales are increasing week over week and more insurances are now covering at Tier 2. Some of the insurances are already covering Trigs > 200 including Tricare. Slow and steady will get us there.
Which parameter do you think that Lovaza is superior in? Mr lol? Ha ha ha .
LDL duh .....
Exactly thank you! We lower them all! 200 and up coming in Dec. Lovaza couldnt we will.lol
